| scholarly article | Q13442814 |
| P50 | author | Kyle Steenland | Q22089123 |
| Antonia M. Calafat | Q28656527 | ||
| P2093 | author name string | Michael I Luster | |
| Nicola Fitz-Simon | |||
| Tony Fletcher | |||
| Ben Armstrong | |||
| Kayoko Kato | |||
| P2860 | cites work | Thirty years of medical surveillance in perfluooctanoic acid production workers | Q46118153 |
| Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. | Q46847931 | ||
| Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers | Q46901755 | ||
| Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. | Q51554496 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. | Q53586587 | ||
| Struggle for Quality in Determination of Perfluorinated Contaminants in Environmental and Human Samples | Q59206292 | ||
| Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers | Q80554158 | ||
| Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate | Q80785516 | ||
| When is baseline adjustment useful in analyses of change? An example with education and cognitive change | Q81908650 | ||
| Improved selectivity for the analysis of maternal serum and cord serum for polyfluoroalkyl chemicals | Q82486634 | ||
| Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities | Q84655272 | ||
| Statins for the primary prevention of cardiovascular disease | Q24234813 | ||
| Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA) | Q24632957 | ||
| Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia | Q24633826 | ||
| The C8 health project: design, methods, and participants | Q24652791 | ||
| Perfluoroalkyl acids: what is the evidence telling us? | Q24685789 | ||
| trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals | Q28377239 | ||
| Evaluation of methods for the measurement of low-density lipoprotein cholesterol. | Q29547378 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers | Q33924739 | ||
| The toxicology of perfluorooctanoate | Q34343282 | ||
| A simulation study of the number of events per variable in logistic regression analysis | Q34411363 | ||
| Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters | Q34571004 | ||
| Perfluoroalkyl acids: a review of monitoring and toxicological findings | Q34630884 | ||
| Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers | Q34680365 | ||
| Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. | Q35008916 | ||
| Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets | Q36721566 | ||
| Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. | Q37103503 | ||
| Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works Facility in West Virginia. | Q39794547 | ||
| Global Validation of Linear Model Assumptions | Q42161717 | ||
| Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay | Q42549325 | ||
| Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid | Q42801273 | ||
| Determination of perfluorinated alkyl acid concentrations in human serum and milk standard reference materials | Q43253712 | ||
| Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. | Q43745356 | ||
| Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations | Q44379609 | ||
| The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome proliferator exposure and withdrawal in mice | Q44569033 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 569-576 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Epidemiology | Q5382707 |
| P1476 | title | Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid | |
| P478 | volume | 24 |
| Q90310069 | Associations between perfluoroalkyl substances and serum lipids in a Swedish adult population with contaminated drinking water |
| Q34273620 | Associations between serum perfluoroalkyl acids and LINE-1 DNA methylation |
| Q92605021 | Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study |
| Q36398116 | County-level hurricane exposure and birth rates: application of difference-in-differences analysis for confounding control |
| Q45972435 | Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. |
| Q57058112 | Health Status of Workers Exposed to Perfluorinated Alkylate Substances |
| Q36629792 | Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice |
| Q36493907 | Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate |
| Q36095017 | Longitudinal measures of perfluoroalkyl substances (PFAS) in serum of Gullah African Americans in South Carolina: 2003-2013. |
| Q28383653 | Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts |
| Q47806217 | Occupational exposure to perfluoroalkyl substances and serum levels of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in an aging population from upstate New York: a retrospective cohort study |
| Q38755871 | PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling |
| Q100444139 | Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research |
| Q62086877 | Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food |
| Q54993802 | Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). |
| Q34474613 | The Madrid Statement on Poly- and Perfluoroalkyl Substances (PFASs) |
Search more.